Chronic Hepatitis C: Implications for Health‐Related Quality of Life

Gastroenterology Nursing

Volumn 24, Issue 4, 2001, Pages 169-175

  Heitkemper, Margaret ^a   Jarrett, Monica ^a   Kurashige, Ella Mae ^b   Carithers, Robert ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

DISEASE COURSE; HEPATITIS C; HUMAN; IMMUNOLOGY; IMMUNOPATHOLOGY; LIVER TRANSPLANTATION; NURSING; QUALITY OF LIFE; REVIEW;

ANTIVIRAL AGENTS; DISEASE PROGRESSION; HEPATITIS C, CHRONIC; HUMANS; IMMUNE SYSTEM DISEASES; INTERFERON-ALPHA; LIVER TRANSPLANTATION; QUALITY OF LIFE;

EID: 0035411028     PISSN: 1042895X     EISSN: 15389766     Source Type: Journal    
DOI: 10.1097/00001610-200107000-00002     Document Type: Article

References (42)

1. Alter, M. J. (1997). Epidemiology of hepatitis C. Hepatology, 26, 62S-65S.
2. Alter, M. J. Mast, E. E., Moyer, L. A., & Margolis, H. S. (1998). Hepatitis C. Infectious Disease Clinics of North America, 12, 13-26.
3. Alter, M. J. Margolis, H. S., Krawczynski, K., Judson, F. N., Mares, A., Alexander, W. J., Hu, P. Y., Miller, J. K., Gerber, M. A., Sampliner, R. E., Meeks, E. L., & Beach, M. J. (1992). The natural history of community-acquired hepatitis in the United States. New England Journal of Medicine, 327, 1899-1905.
4. Bayliss, M. S., Gandek, B., Bungay, K. M., Sugano, D., Hsu, M. A., & Ware, J. E., Jr. (1998). A questionnaire to assess the generic and disease-specific health outcomes of patients with chronic hepatitis C. Quality of Life Research, 7(1), 39-55.
5. Bayliss, M. S. (1999). Methods in outcomes research in hepatology: Definitions and domains of quality of life. Hepatology, 29 (Suppl. 6), 3S-6S.
6. Bonkovsky, H. L., & Woolley, J. M. (1999) Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group. Hepatology, 29(1), 264-270.
7. Brebner, K., Hayley, S., Zacharko, R., Merali, Z., & Anisman, H. (2000). Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: Central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology, 22(6), 566-580.
8. Cannon, G. J. G., & St.Pierre, B. A. (1997). Gender differences in host defense mechanisms. Journal of Psychiatric Research, 31, 99-113.
9. Carithers, R. L. Jr., Sugano, D., & Bayliss, M. (1996). Health assessment for chronic HCV infection: Results of quality of life. Digestive Diseases Sciences, 41(Suppl. 12), 75S-80S.
10. Cotler, S. J., Wartelle, C. F., Larson, A. M., Gretch, D. R., Jensen, D. M., & Carithers, Jr R. L. (2000). Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C. Journal of Viral Hepatology, 7(3), 211-217.
11. Cozzolongo, R., Cuppone, R., Giannuzzi, V., Amati, L., Caradonna, L., Tamborrino, V., Jirillo, E., & Manghisi, O. G. (2001). Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. Alimentary Pharmacology &ardt, F. (1990). Long Therapeutics, 15(1), 129-135.
12. Davis, G. L., Albright, J. E., Cook, S., & Rosenberg, D. (1998). Projecting the future health care burden from hepatitis C in the United States. Hepatology, 28, 390A.
13. Davis, G. L., Balart, L. A., Schiff, E. R., Lindsay, K., Bodenheimer, H. C. Jr., Perrillo, R. P., Carey, W., Jacobson, I. M., Payne, J., Dienstag, J. L., VanThiel, D. H., Tamburro, C., Martino, F. P., Sangvhi, B., & Albrecht, J. K. (1994). Assessing health-related quality of life in chronic hepatitis C using the Sickness Impact Profile. Clinical Therapeutics, 16(2), 334-343.
14. Dickson, R. C., Wright, R. M., Bacchetta, M. D., Bodily, S. E., Caldwell, S. H., Driscoll, C. J., Pruett, T. L., & Ishitani, M. B. (1997). Quality of life of hepatitis B and C patients after liver transplantation. Clinical Transplant, 11(4), 282-285.
15. Diener, E., & Suh, E. (1997). Measuring quality of life: Economic, social, and subjective indicators. Social Indicators Research, 40, 189-216.
16. Farci, P., Alter, H. J., Govindarajan, S., Wong, D. C., Engle, R., Lesniewski, R. R., Mushahwar, I. K., Desai, S. M., Miller, R. H., Ogata, N., & Purcell, R. H. (1992). Lack of protective immunity against reinfection with hepatitis C. Science, 258, 135-140.
17. Farci, P., Alter, H. J., Wong, D., Miller, R. H., Shih, J. W., Jett, B., & Purcell, R. H. (1991). A long-term study of hepatitis C virus replication in non-A, non-B hepatitis. New England Journal of Medicine, 325, 98-104.
18. Fattovich, G., Giustina, G., Degos, F., Tremolada, F., Diodati, G., Almasio, P., Nevens, F., Solinas, A., Mura, D., Brouwer, J.T., Thomas, H., Njapoum, C., Casarin, C., Bonetti, P., Fuschi, P., Basho, J., Tocco, A., Bhalla, A., Galassini, R., Noventa, F., Schalm, S.W., & Realdi, G. (1997). Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology, 112, 463-472.
19. Foster, G. R., Goldin, R. D., Thomas, H. C.(1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27(1), 209-212.
20. Gayowski, R., Wagener, M. M., Marino, I. R., & Singh, N. (1999). Quality of life and functional status of liver transplant recipients with recurrent viral hepatitis C. Transplantation Proceedings, 31, 1386-1387.
21. Goh, J., Coughlan, B., Quinn, J., O'Keane, J. C., Crowe, J. (1999). Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Hepatology, 30(2), 550-555.
22. Gordon, F. D. (1999). Cost-effectiveness of screening patients for hepatitis C. American Journal of Medicine, 27, 36S-40S.
23. Gretch, D. R., Polyak, S. J., Wilson, J. J., Carithers, R. L., Jr., Perkins, J. D., & Corey, L. (1996). Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. Journal of Virology, 70, 7622-7631.
24. Hopf, U., Moller, B., Kuther, D., Stemerowicz, R., Lobeck, H., Ludtke-Handjery, A., Walter, E., Blum, H. E., Roggendorf, M., & Deinhardt, F. (1990). Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-b and frequency of circulating antibodies to hepatitis C virus HCV. Journal of Hepatology, 10, 69-76.
25. Kage, M., Shimamatu, K., Nakashima, E., Kojiro, M., Inoue, O., & Yano, M. (1997). Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C. Hepatology, 25(4), 1028-1031.
26. Kiyosawa, K., Akahane, Y., Nagata, A., Koike, Y., & Furuta, S. (1982). The significance of blood transfusion in non-A, non-B chronic liver disease in Japan. Vox Sanguinis, 43(1), 45-52.
27. Koff, R. S. (1999). Impaired health-related quality of life in chronic hepatitis C: The how, but not the why. Hepatology, 29, 277-279.
28. McGuinness, P. H., Painter, D., Davies, S., & McCaughan, G. W. (2000). Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection. Gut, 46(2), 260-269.
29. Nasir, A., Arora, H. S., & Kaiser, H. E. (2000). Apoptosis and pathogenesis of viral hepatitis C—an update. In Vivo, 14(1), 297-300.
30. Neuman, M. G., Benhamou, J. P., Martinot, M., Boyer, N., Shear, N. H., Malkiewicz, I., Katz, G. G., Suneja, A., Singh, S., & Marcellin, P. (1999). Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. Clinical Biochemistry, 32(7), 537-545.
31. Painter, P. L., Luetkemeier, M. J., Moore, G. E., Dibble, S. L., Green, G. A., Myll, J. O., & Carlson, L. L. (1997). Health-related fitness and quality of life in organ transplant recipients. Transplantation, 64(12), 1795-1800.
32. Paterson, D. L., Gayowski, T., Wannstedt, C. F., Wagener, M. M., Marino, I.R., Vargas, H., Laskus, T., Rakela, J., & Singh, N. (2000). Quality of life in long-term survivors after liver transplantation: Impact of recurrent viral hepatitis C virus hepatitis. Advances in Internal Medicine, 45, 65-105.
33. Poynard, T., Bedossa, P., & Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet, 349, 825-832.
34. Purcell, R. (1997). The hepatitis C virus: Overview. Hepatology, 26, 11S-14S.
35. Rodger, A. J., Jolley, D., Thompson, S. C., Lanigan, A., Crofts, N. (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology, 30(5), 1299-1301.
36. Schwimmer, J. B., & Balistreri, W. F. (2000). Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population. Seminars in Liver Disease, 20(1), 37-46.
37. Seeff, L. B., Buskell-Bales, Z., Wright, E. C., Durako, S. J., Alter, H. J., Iber, F. L., Hollinger, F. B., Gitnick, G., Knodell, R. G., Perrillo, R. P., et al. (1992). Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group. New England Journal of Medicine, 327(27), 1906-1911.
38. Shepherd, J., Waugh, N., & Hewitson, P. (2000). Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: A rapid and systematic review. Health & Technology Assessment, 4(33), 1-67.
39. Takahashi, M., Yamada, G., Miyamoto, R., Doi, T., Endo, H., & Tsuji, T. (1993). Natural course of chronic hepatitis C. American Journal of Gastroenterology, 88, 240-243.
40. Tong, M. J., El-Farra, N. S., Reikes, A. R., & Co, R. L. (1995). Clinical outcomes after transfusion-associated hepatitis C. New England Journal of Medicine, 332, 1463-1466.
41. Ware, J. E., Jr., Kosinski, M., & Keller, S. (1994). The SF-36 physical and mental summary measures: A user's manual. Boston: The Health Institute New England Medical Center.
42. Williams, I. (1999). Epidemiology of hepatitis C in the United States. American Journal of Medicine, 107(6B), 2S-9S.